Prolific Machines has announced a partnership with Zylidac Bio, a CDMO located in the San Francisco Bay Area, to scale up the production of Prolific’s cell lines. This collaboration focuses on transitioning from development scale to GMP manufacturing for clinical and commercial supply. Prolific has demonstrated success with industry-leading yields across mAbs and difficult-to-express proteins.
Strategic Partnerships and Expansion
This investment, led by Atoms & Bits and Nant Capital, supports Prolific’s expansion of its optogenetics platform for biomanufacturing. The funding will be used for team growth, technology development, and scale-up across biologics, biosimilars, and viral vector programs. Early work toward tissue and organ fabrication is also planned.
Leadership Perspectives
A strategic collaboration has been established between Prolific Machines and NantWorks to apply Prolific’s platform across biologic programs within NantWorks’ portfolio. The goal is to provide infrastructure for controlling biology with precision and low cost. Prolific has demonstrated that the technology can be scaled and is in demand. Deniz Kent, Ph.D., CEO of Prolific Machines, and Patrick Soon-Shiong, M.D., founder of NantWorks, both highlighted the significance of this advancement in biopharma manufacturing, anticipating rapid business scaling over the next 12 months.